Literature DB >> 26280090

The effects of Kv1.3 and IKCa1 channel inhibition on cytokine production and calcium influx of T lymphocytes in rheumatoid arthritis and ankylosing spondylitis.

Gergely Toldi1,2, Luis Munoz3, Martin Herrmann3, Georg Schett3, Attila Balog4.   

Abstract

Kv1.3 and IKCa1 lymphocyte potassium channels have been implicated as important targets of selective immunomodulation. We compared the alterations in cytokine production upon selective inhibition of Kv1.3 or IKCa1 channels (by MGTX and TRAM, respectively) in healthy donors (HD), RA and AS patients. We also determined calcium influx kinetics and its sensitivity to Kv1.3 and IKCa1 channel inhibition following PHA activation in CD4, Th1, Th2 and CD8 cells as well as monocytes. The application of TRAM resulted in a lower production of TNF-a and IL1-RA in all three study groups. Inhibition by TRAM had contrary effects on the production of IL-1b and IL-5: While their production was increased by PBMCs of RA patients, this effect was not observed in HD and AS PBMCs. While treatment with MGTX resulted in a similar decrease in calcium influx in the CD4 and Th2 subsets across all study groups, TRAM treatment had opposite effects on RA and HD samples: It decreased calcium influx in the Th2 and CD8 subsets in RA, while only Th1 cells were affected in HDs. The effects of IKCa1 channel inhibition are controversial in samples of RA and AS patients, since it shifts the inflammatory balance into the pro-inflammatory direction.

Entities:  

Keywords:  AS; Calcium influx; Cytokine; IKCa1; Kv1.3; RA

Mesh:

Substances:

Year:  2016        PMID: 26280090     DOI: 10.1007/s12026-015-8683-8

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  6 in total

1.  Cytometry-acquired calcium-flux data analysis in activated lymphocytes.

Authors:  A S Kaposi; G Veress; B Vásárhelyi; P Macardle; S Bailey; T Tulassay; A Treszl
Journal:  Cytometry A       Date:  2008-03       Impact factor: 4.355

2.  The effects of Kv1.3 and IKCa1 potassium channel inhibition on calcium influx of human peripheral T lymphocytes in rheumatoid arthritis.

Authors:  Gergely Toldi; Anna Bajnok; Diána Dobi; Ambrus Kaposi; László Kovács; Barna Vásárhelyi; Attila Balog
Journal:  Immunobiology       Date:  2012-05-23       Impact factor: 3.144

3.  Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases.

Authors:  Christine Beeton; Heike Wulff; Nathan E Standifer; Philippe Azam; Katherine M Mullen; Michael W Pennington; Aaron Kolski-Andreaco; Eric Wei; Alexandra Grino; Debra R Counts; Ping H Wang; Christine J LeeHealey; Brian S Andrews; Ananthakrishnan Sankaranarayanan; Daniel Homerick; Werner W Roeck; Jamshid Tehranzadeh; Kimber L Stanhope; Pavel Zimin; Peter J Havel; Stephen Griffey; Hans-Guenther Knaus; Gerald T Nepom; George A Gutman; Peter A Calabresi; K George Chandy
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-06       Impact factor: 11.205

4.  Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes.

Authors:  Lina Hu; Michael Pennington; Qiong Jiang; Katharine A Whartenby; Peter A Calabresi
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

5.  Thrombospondin-1 and transforming growth factor beta are pro-inflammatory molecules in rheumatoid arthritis.

Authors:  Mario C Rico; Joanne M Manns; Jeffrey B Driban; Audrey B Uknis; Satya P Kunapuli; Raul A Dela Cadena
Journal:  Transl Res       Date:  2008-07-11       Impact factor: 7.012

6.  Calcium movement and membrane potential changes in the early phase of neutrophil activation by phorbol myristate acetate: a study with ion-selective electrodes.

Authors:  C Mottola; D Romeo
Journal:  J Cell Biol       Date:  1982-04       Impact factor: 10.539

  6 in total
  1 in total

Review 1.  Updated review on immune factors in pathogenesis of Crohn's disease.

Authors:  Na Li; Rui-Hua Shi
Journal:  World J Gastroenterol       Date:  2018-01-07       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.